A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Aug 2018.